ALK and non-small cell lung carcinoma: To be brief, first-line immunotherapy combined with chemotherapy has rapidly expanded first-line treatment options for advanced NSCLC patients without sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusions.